Treatment strategies and outcomes in a long-term registry study of patients with high-risk metastatic hormone-naïve prostate cancer in Japan: An interim analysis of the J-ROCK study.
Hirotsugu UemuraRikiya MatsumotoAtsushi MizokamiHideaki MiyakeHiroji UemuraHideyasu MatsuyamaKazuyoshi NakamuraKazutaka SaitoMutsushi KawakitaHideki TakeshitaYosuke KorokiShintaro OnoMaiko MurotaMiku ItoToshiyuki KamotoKiyohide FujimotoPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
The higher proportion of cohort 2 suggest a paradigm shift has occurred in the real-world treatment of high-risk metastatic hormone-naïve prostate cancer in Japan. Some factors including prostate-specific antigen may affect treatment selection but need further observation. Most patients in cohort 2 received abiraterone acetate+prednisolone. The proportion of patients in cohort 1 receiving combined androgen blockade was lower than previously reported in Japan. This analysis suggest that more intensive therapy tends to prolong prostate-specific antigen-progression-free survival in patients with high-risk metastatic hormone-naïve prostate cancer.
Keyphrases
- prostate cancer
- end stage renal disease
- radical prostatectomy
- squamous cell carcinoma
- small cell lung cancer
- newly diagnosed
- ejection fraction
- chronic kidney disease
- free survival
- peritoneal dialysis
- skeletal muscle
- metabolic syndrome
- mesenchymal stem cells
- patient reported outcomes
- combination therapy
- bone marrow
- replacement therapy
- patient reported
- glycemic control